A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

Conditions

• Multiple Myeloma, Plasma Cell Leukemia

Interventions

• DRUG: ARRY-520, KSP(Eg5) inhibitor; intravenous
• DRUG: Bortezomib, proteasome inhibitor; intravenous or subcutaneous
• DRUG: Dexamethasone, steroid; oral
• DRUG: Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous
• DRUG: ARRY-520, KSP(Eg5) inhibitor; intravenous
• DRUG: Bortezomib, proteasome inhibitor; intravenous or subcutaneous
• DRUG: Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous

Sponsor

Array Biopharma, now a wholly owned subsidiary of Pfizer